NVS Ends NSCLC Drug Enrollment – Analyst Blog
Source: http://www.zacks.com/stock/news/24417/NVS+Ends+NSCLC+Drug+Enrollment+-+Analyst+BlogPosted on Wednesday, September 2nd, 2009 | In Stocks to Watch
Yesterday, patient enrollment (1200) for a phase III trial of ASA404, jointly developed by Novartis (NVS) and Antisoma for the treatment of non small-cell lung cancer (NSCLC) was completed. Novartis is conducting the trial as the development and commercialization partner (for ASA404) of Antisoma.
The trial will be conducted to test the effectiveness of the drug as a first-line treatment for squamous and non-squamous NSCLC with results due in 2010 or early 2011. The company expects to file for approval in 2011 if the trial results are positive. In addition to this, Novartis will be conducting another study of the drug in previously treated patients.
Lung cancer kills 1.3 million people a year and is one of the leading causes of cancer death across the world. NSCLC accounting for about 87% of all lung cancer patients is one of the leading causes of death. Survival rates are very poor in this class, which kills more patients than breast, colon and prostate cancer together. Only 15% of patients live more than 5 years, primarily because of the late diagnosis of the disease.
There are several companies like Pfizer (PFE) and Cell Therapeutics (CTIC) with drugs under different stages of development targeting diseases such as NSCLC. Merck KGaA is developing Stimuvax (a cancer vaccine) currently under phase III trial for the treatment of patients with NSCLC, multiple myeloma and breast cancer.
Chemotherapy used to be the main treatment, but with many new therapies under development, the scenario is likely to change. Chemotherapy is expected to account for only 36% of treatment in 2014 (dropping from 68% in 2007).
Read the full analyst report on “NVS”
Read the full analyst report on “PFE”
Read the full analyst report on “CTIC”
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- VIP Falls Behind Expectations - Analyst Blog - November 25th, 2009
- J. Crew Beats Zacks Estimates - Analyst Blog - November 25th, 2009
- No Change in Deere's Outlook - Analyst Blog - November 25th, 2009
- Sprint Acquires Virgin Mobile USA - Analyst Blog - November 25th, 2009
- Provenge Action Date Assigned - Analyst Blog - November 25th, 2009
Analyst, ASA404, Breast Cancer, cancer, Chemotherapy, Colon Cancer, Lung Cancer, Merck KGaA, multiple myeloma, Novartis, Novartis AG, NSCLC;, Pfizer, Prostate Cancer, Stimuvax, Stocks to Watch, treatment of non-small cell lung cancer, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.